Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Figures & data

Table I. Baseline clinical and laboratory features of the 10 CML patients carrying CVTs.

PPN	Sex	Age	Sokal score	Euro score	CML phase	BCR-ABL transcript	Karyotype
11	M	29	LOW	LOW	CP	el3a2(b2a2)	46, XY, t (7;9;22)
47	M	44	INT	LOW	CP	el4a2(b3a2)	46, XY, t (2;6;9;22)
51	M	35	LOW	LOW	CP	el4a2(b3a2)	46, XY, t (9;22;15)
69	M	59	INT	HIGH	CP	el3a2(b2a2)	46, XY, t (9;11;21;22)
101	F	64	INT	LOW	CP	el3a2(b2a2)	46, XX, t (9;17;22)
113	M	55	LOW	INT	CP	el4a2(b3a2)	46, XY, t (9;22;8)
124	M	38	LOW	LOW	CP	el3a2(b2a2)	46, XY, t (9;22;8)
136	M	69	INT	INT	CP	el3a2(b2a2)	46, XY, t (4;22;9)
143	M	74	INT	HIGH	CP	el3a2(b2a2)	46, XY, t (9;22;12)
156	M	66	LOW	LOW	CP	el3a2(b2a2)	46, XY, t (9;22;17)

Abbreviation: Chronic Phase (CP).

Table II. Cytogenetic (CyR) and molecular (MolR) responses to tyrosine kinase inhibitors (TKIs).

PPN	TKI	CyR at 6 months (% Phi)	CyR at 12 months (% Phi)	CyR at 18 months (% Phi)	MolR^IS at 18 months	Response to TKI
11	IM	0	0	0	0.04	Optimal
47	IM	30	5	NA	NA	Suboptimal CyR at 12 months
51	IM	0	0	0	0.24	Sub optimal MolR
69	NIL	0	0	0	0.25	Suboptimal MolR
101	IM	0	0	0	0.00	Optimal
113	IM	0	0	0	0.28	Suboptimal MolR
124	IM	10	3	1	1.38	Failure
136	NIL	0	0	0	1.20	Suboptimal MolR
143	IM	0	0	0	1.30	Suboptimal MolR
156	IM	25	0	0	0.15	Suboptimal MolR

Abbreviation: Imatinib (IM), Nilotinib (NIL), Not applicable (NA).